Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.35) per share. This is a 47.76 percent increase over losses of $(0.67) per share from the same period last year.
Barrington Research Initiates Coverage On Crawford & Company Common Stock with Outperform Rating, Announces Price Target of $13
Barrington Research analyst Kevin Steinke initiates coverage on Crawford & Company Common Stock (NYSE:CRD) with a Outperform rating and announces Price Target of $13.
